Fairfield, Bush & Co’s CRISPR Therapeutics CRSP Stock Holding History

Fairfield, Bush & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,720	Closed	-$269K	–	113
2024 Q3	$269K	Sell	5,720 -305	-5%	-$15.5K	0.16%	92
2024 Q2	$325K	Buy	6,025 +1,000	+20%	+$57.8K	0.2%	79
2024 Q1	$343K	Buy	5,025 +2,850	+131%	+$204K	0.2%	86
2023 Q4	$136K	Buy	+2,175	New	+$120K	0.08%	129
2023 Q3	–	Sell	-5,150	Closed	-$289K	–	182
2023 Q2	$289K	Hold	5,150	–	–	0.08%	129
2023 Q1	$233K	Buy	+5,150	New	+$250K	0.08%	134
2022 Q3	–	Sell	-590	Closed	-$36K	–	179
2022 Q2	$36K	Buy	+590	New	+$34.7K	0.02%	216
2021 Q4	–	Sell	-3,450	Closed	-$386K	–	138
2021 Q3	$386K	Buy	+3,450	New	+$433K	0.13%	121

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fairfield, Bush & Co's CRSP Position: Q4 2024 in Review

Fairfield, Bush & Co sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 5,720 shares — an estimated $269K sold.

Fairfield, Bush & Co first reported a position in CRSP in Q3 2021 and held it in 8 quarters. The position peaked at $386K in Q3 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Fairfield, Bush & Co reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Fairfield, Bush & Co sold 5,720 CRISPR Therapeutics shares in Q4 2024, an estimated $269K.
Fairfield, Bush & Co first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 8 quarters.
Fairfield, Bush & Co's CRISPR Therapeutics position peaked at $386K in Q3 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Fairfield, Bush & Co's 13F filing for Q4 2024, filed 13 Feb 2025.